Table 3.
Percentage inhibition of cancer cell proliferation and IC50 values
|
Sample |
Type of cell line |
|||||||
|---|---|---|---|---|---|---|---|---|
| |
Colo – 205 |
Y79 |
HepG2 |
SupT1 |
||||
| %age Inhibition | IC50 Value | % age Inhibition | IC50 Value | % age Inhibition | IC50 Value | % age Inhibition | IC50 Value | |
|
APE (200 μg/mL) |
68.33 ± 1.41* |
29.57 ± 2.02 |
66.40 ± 5.44* |
35.94 ± 2.10 |
53.33 ± 1.21* |
44.31 ± 3.07 |
61.34 ± 1.32* |
37.00 ± 2.38 |
|
APA (200 μg/mL) |
92.25 ± 2.05*** |
18.91 ± 1.06 |
92.80 ± 6.34* |
26.74 ± 1.34 |
88.52 ± 3.04** |
27.03 ± 1.03 |
94.12 ± 3.34** |
26.89 ± 3.24 |
|
Doxorubicin (Standard) 10 μg/mL |
94.81 ± 3.42 |
0.41 ± 0.08 |
94.20 ± 4.11 |
0.39 ± 0.10 |
89.18 ± 3.42 |
0.47 ± 0.08 |
95.20 ± 3.11 |
0.39 ± 0.11 |
| DMSO 2% (Solvent control) | 6.67 ± 1.67 | -- | 3.33 ± 0.78 | -- | 3.13 ± 1.01 | -- | 4.33 ± 0.78 | -- |
Values were the means of four replicates ± standard deviation (SD). Significant p value (*** p < 0.001, ** p < 0.01 and * p <0.05 were obtained by Student’s t test analysis. Composite treatments were compared using one-way analysis of variances (ANOVA) and probability values were found to be equal to or less than 0.05 for all the four cell lines.